5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.58▲ | 0.57▲ | 0.57▲ | 0.57▲ | 1.22▼ |
MA10 | 0.57▲ | 0.57▲ | 0.57▲ | 0.69▼ | 1.77▼ |
MA20 | 0.57▲ | 0.57▲ | 0.57▲ | 1.41▼ | 2.09▼ |
MA50 | 0.57▲ | 0.58▲ | 0.60▼ | 1.98▼ | 2.79▼ |
MA100 | 0.58▲ | 0.80▼ | 1.29▼ | 2.20▼ | 7.95▼ |
MA200 | 0.62▼ | 1.57▼ | 1.89▼ | 2.77▼ | 26.70▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.003▲ | 0.004▲ | 0.014▲ | -0.077▼ | -0.113▼ |
RSI | 67.711▲ | 59.373▲ | 48.097▼ | 14.197▼ | 24.469▼ |
STOCH | 100.000▲ | 44.863 | 40.204 | 4.510▼ | 11.396▼ |
WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -96.476▼ | -97.280▼ |
CCI | 204.174▲ | 237.680▲ | 241.104▲ | -54.844 | -175.328▼ |
Wednesday, September 10, 2025 06:13 AM
A Phase 2 study for NT219 in combination with immunotherapy is being conducted in collaboration with the University of Colorado REHOVOT, Israel, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd.
|
Friday, September 05, 2025 01:12 PM
Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance ...
|
Thursday, September 04, 2025 06:15 AM
$6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/09/25 | 0.5756 | 0.597 | 0.5756 | 0.597 | 480,340 |
15/09/25 | 0.58 | 0.58 | 0.5555 | 0.5654 | 426,708 |
12/09/25 | 0.59 | 0.59 | 0.55 | 0.5705 | 499,565 |
11/09/25 | 0.5765 | 0.59 | 0.5326 | 0.57 | 693,110 |
10/09/25 | 0.6092 | 0.63 | 0.5501 | 0.5612 | 1,206,189 |
09/09/25 | 0.59 | 0.63 | 0.57 | 0.5925 | 950,927 |
08/09/25 | 0.621 | 0.6289 | 0.59 | 0.599 | 1,545,432 |
05/09/25 | 0.752 | 0.752 | 0.595 | 0.66 | 3,219,495 |
04/09/25 | 0.8793 | 0.9153 | 0.715 | 0.78 | 47,296,004 |
03/09/25 | 1.42 | 1.4893 | 1.27 | 1.42 | 305,937 |
|
|
||||
|
|
||||
|
|